A randomized, controlled, multicenter, open-label comparing a hospital post discharge care pathway involving aggressive LDL-C Management that includes inclisiran with usual care alone in patient with recent acute coronary syndrome (VICTORIAN-INCEPTION)

PI: Samar Sheth, MD

Sponsor: Novartis Pharmaceuticals Corporation


Eligibility Requirements

– Males and females ≥18 years of age
– Recent ACS (in-patient/out-patient) within 5 weeks of screening, defined as: Ischemic symptoms with unstable pattern, occurring at rest or minimal exertion within 24 hours of an unscheduled hospital admission or emergency department visit, due to presumed or proven obstructive coronary disease AND at least one of the following:

a. Elevated cardiac biomarkers
b. Resting ECG changes consistent with ischemia or infarction AND additional evidence of obstructive coronary disease

– Serum LDL-C ≥70 mg/dL or non-HDL-C ≥100 mg/dL
– Calculated eGFR >20mL/min
– Fasting triglycerides < 4.52mmol/L